9.31
0.00
(0.00%)
May 20 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.15 - 9.47 |
| 52 week | 6.25 - 12.00 |
| Open | 9.20 |
| Vol / Avg. | 0.00/21,964.00 |
| Mkt cap | 198.20M |
| P/E | - |
| Div/yield | - |
| EPS | -1.69 |
| Shares | 21.29M |
| Beta | - |
| Inst. own | 69% |
Events
May 30, 2013
Marcum MicroCap Conference
- 4:00PM EDT -
May 29, 2013
Deutsche Bank dbAccess Health Care Conference
- 4:50PM EDT -
May 22, 2013
Sachs Associates CANCER BIO PARTNERING FORUM Promoting Public & Private Sector,Collaboration & Investment in Drug Development
- 10:30AM EDT -
May 22, 2013
UBS Global Healthcare Conference
- 8:30AM EDT -
May 9, 2013
Verastem Inc Annual Stockholders Meeting
May 1, 2013
Needham Healthcare Conference -
Apr 22, 2013
BIO International Convention; Business Forum
Apr 7, 2013
Scientific Data Presentations at AACR
Apr 5, 2013
BioCentury Publications Future Leaders in the Biotech Industry Conference
Apr 4, 2013
Xconomy Forum: Boston Biotech Seizes the Momentum
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -40.46% | -42.10% |
| Return on average equity | -41.83% | -82.34% |
| Employees | 24 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 440, 215 First St.
CAMBRIDGE, MA 02142
United States - Map
+1-617-2529300 (Phone)
+1-914-9499618 (Fax)
CAMBRIDGE, MA 02142
United States - Map
+1-617-2529300 (Phone)
+1-914-9499618 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
Verastem, Inc. is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis. It is translating discoveries in cancer stem cell research into new medicines for the treatment of cancers such as breast cancer.
Officers and directors
| Christoph H. Westphal M.D., Ph.D. | Chairman of the Board, Chief Executive Officer | |
| Robert Forrester | President, Chief Operating Officer | |
| John B. Green | Chief Financial Officer | |
| Jonathan Pachter Ph.D. | Vice President, Head - Research | |
| Joanna C. Horobin M.D. | Chief Medical Officer | |
| Michael G. Kauffman M.D., Ph.D. | Director | |
| Alison Lawton | Director | |
| S. Louise Phanstiel | Director | |
| Stephen A. Sherwin M.D. | Director | |
| Richard Aldrich | Independent Director |